Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: Comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression

Experimental Hematology

Volumn 38, Issue 5, 2010, Pages 351-362

  Decot, Véronique ^a,b   Voillard, Laure ^a   Latger Cannard, Véronique ^a   Aissi Rothé, Lamia ^a,b   Perrier, Pascale ^a   Stoltz, Jean Francois ^a,b   Bensoussan, Daniele ^a,b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; HLA ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; NATURAL KILLER CELL RECEPTOR NKG2D; REAGENT;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; B LYMPHOCYTE; CELL CULTURE; CELL EXPANSION; CELL ISOLATION; CELL SELECTION; CLINICAL PROTOCOL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE AMPLIFICATION; GOOD MANUFACTURING PRACTICE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA TYPING; HUMAN; HUMAN CELL; INCUBATION TIME; LEUKEMIA RELAPSE; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; T LYMPHOCYTE;

CELL DIVISION; CELL SEPARATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HLA ANTIGENS; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-15; INTERLEUKIN-2; INTERLEUKIN-7; KILLER CELLS, NATURAL; LEUKEMIA; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, KIR2DL1; RECEPTORS, KIR2DL2;

EID: 77951499495     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.02.006     Document Type: Article

References (28)

1. Barnes D.W., Loutit J.F. Treatment of murine leukaemia with x-rays and homologous bone marrow. II. Br J Haematol 1957, 3:241-252.
2. Fefer A. Graft-vs-tumor responses. Thomas' Hematopoietic Cell Transplantation 2004, Blackwell publishing Ltd, Oxford, UK, p. 369-379. 3rd ed. K.G. Blume, S.J. Forman, F.R. Appelbaum (Eds.).
3. Bonnet D., Warren E.H., Greenberg P.D., Dick J.E., Riddell S.R. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci U S A 1999, 96:8639-8644.
4. Hambach L., Spierings E., Goulmy E. Risk assessment in haematopoietic stem cell transplantation: minor histocompatibility antigens. Best Pract Res Clin Haematol 2007, 20:171-187.
5. Biron C.A., Nguyen K.B., Pien G.C., Cousens L.P., Salazar-Mather T.P. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999, 17:189-220.
6. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989, 47:187-376.
7. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
8. Velardi A. Role of KIRs and KIR ligands in hematopoietic transplantation. Curr Opin Immunol 2008, 20:581-587.
9. Hsu K.C., Keever-Taylor C.A., Wilton A., et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005, 105:4878-4884.
10. Verheyden S., Schots R., Duquet W., Demanet C. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 2005, 19:1446-1451.
11. Lang P., Pfeiffer M., Handgretinger R., et al. Clinical scale isolation of T cell-depleted CD56+ donor lymphocytes in children. Bone Marrow Transplant 2002, 29:497-502.
12. Bamford R.N., Grant A.J., Burton J.D., et al. The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A 1994, 91:4940-4944.
13. Giri J.G., Ahdieh M., Eisenman J., et al. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 1994, 13:2822-2830.
14. Rosenberg S.A., Lotze M.T., Muul L.M., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985, 313:1485-1492.
15. McKenna D.H., Sumstad D., Bostrom N., et al. Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion 2007, 47:520-528.
16. Farag S.S., Fehniger T.A., Ruggeri L., Velardi A., Caligiuri M.A. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002, 100:1935-1947.
17. Curtis R.E., Travis L.B., Rowlings P.A., et al. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 1999, 94:2208-2216.
18. Passweg J.R., Stern M., Koehl U., Uharek L., Tichelli A. Use of natural killer cells in hematopoetic stem cell transplantation. Bone Marrow Transplant 2005, 35:637-643.
19. Bethge W.A., Faul C., Bornhauser M., et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: An update. Blood Cells Mol Dis 2008, 40:13-19.
20. Berg M., Lundqvist A., McCoy P., et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009, 11:341-355.
21. Koehl U., Esser R., Zimmermann S., et al. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin Padiatr 2005, 217:345-350.
22. Alici E., Sutlu T., Bjorkstrand B., et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 2008, 111:3155-3162.
23. Carson W.E., Fehniger T.A., Haldar S., et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 1997, 99:937-943.
24. Cooper M.A., Bush J.E., Fehniger T.A., et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 2002, 100:3633-36338.
25. Szczepanski M.J., Szajnik M., Welsh A., Foon K.A., Whiteside T.L., Boyiadzis M. Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunol Immunother 2010, 59:73-79.
26. Lum J.J., Schnepple D.J., Nie Z., et al. Differential effects of interleukin-7 and interleukin-15 on NK cell anti-human immunodeficiency virus activity. J Virol 2004, 78:6033-6042.
27. Poggi A., Catellani S., Garuti A., Pierri I., Gobbi M., Zocchi M.R. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia 2009, 23:641-648.
28. Cerwenka A., Lanier L.L. NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 2003, 61:335-343.